A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

  • Sarah Lapointe
  • Warren Mason
  • Mary MacNeil
  • Craig Harlos
  • Roger Tsang
  • Joana Sederias
  • H. Artee Luchman
  • Samuel Weiss
  • John P. Rossiter
  • Dongsheng Tu
  • Lesley Seymour
  • Martin SmoragiewiczEmail author


The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies. Inhibition of the PI3K pathway has been shown to sensitize cultured glioma cells and tumor xenografts to the effects of temozolomide (TMZ) and radiation. Vistusertib is an oral inhibitor of mTORC1/2 complexes. The primary objective of this Canadian Cancer Trials Group phase I study was to determine the recommended phase II dose (RP2D) of vistusertib in patients with GBM receiving TMZ at first progression following primary treatment. Vistusertib was administered at a starting dose of 100 mg bid 2 days on/5 days off weekly with TMZ 150 mg/m2 daily for 5 days/28-days cycle. Dose escalation was according to a 3 + 3 design. Secondary objectives included assessment of vistusertib safety and toxicity profile, and preliminary efficacy. 15 patients were enrolled in the study (median age 66 (range 51–77), females 8). Vistusertib 125 mg BID in combination with TMZ 150 mg/m2 daily for 5 days was well tolerated. Vistusertib treatment-related adverse events were generally grade 1–2, with the most frequently reported being fatigue, gastrointestinal symptoms, and rash. Of 13 response evaluable patients, 1 patient (8%) had a partial response ongoing at 7.6 months of follow-up, and 5 patients had stable disease (38%) as best response (median duration 9.6 months, range 3.7-not yet reached). Six-month progression-free survival (PFS) rate was 26.6%. Combination of vistusertib with TMZ in GBM patients at first recurrence demonstrated a favorable safety profile at the tested dose levels.


Clinical trial Glioblastoma Temozolomide mTOR inhibitor mTORC2 AZD2014 



The authors acknowledge support from the Canadian Cancer Society and Terry Fox Research Institute. The authors acknowledge Dr. Gregory Cairncross for his leadership heading the TFRI GBM Consortium and support in this collaboration.


Financial support was provided by grants from the Canadian Cancer Society (grant # 704970) and Terry Fox Research Institute (grant # 2009–20). This research was conducted with the support from AstraZeneca Canada Inc., which provided study drug.

Compliance with ethical standards

Conflict of interest

Dr. Seymour received funding from AstraZeneca on behalf of CCTG, and holds shares in AstraZeneca. No other authors declared any conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Ostrom QT, Gittleman H, Truitt G et al (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:iv1–iv86. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136. CrossRefPubMedGoogle Scholar
  3. 3.
    Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. CrossRefPubMedGoogle Scholar
  4. 4.
    Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954–1963. CrossRefPubMedGoogle Scholar
  5. 5.
    Schiff D, Jaeckle KA, Anderson SK et al (2018) Phase 1 / 2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma : north central cancer treatment group study / alliance N0572. Cancer 1455–1463. CrossRefGoogle Scholar
  6. 6.
    Mecca C, Giambanco I, Donato R, Arcuri C (2018) Targeting mTOR in glioblastoma: rationale and preclinical/clinical evidence. Dis Markers 2018:1–10. CrossRefGoogle Scholar
  7. 7.
    Zhao H, Wang J, Shao W et al (2017) Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 16:100. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bahmad HF, Mouhieddine TH, Chalhoub RM et al (2018) The Akt / mTOR pathway in cancer stem / progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma. Oncotarget 9:33549–33561. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhavoronkov A (2015) Inhibitors of mTOR in aging and cancer. Oncotarget 6:45011. CrossRefGoogle Scholar
  10. 10.
    Choi EJ, Cho BJ, Lee DJ et al (2014) Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 14:1–12. CrossRefGoogle Scholar
  11. 11.
    Choe G, Horvath S, Cloughesy TF et al (2003) Analysis of the PI3K signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMedGoogle Scholar
  12. 12.
    Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075–1083. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Network TCGAR (2008) Comprehensive genomic characterization defines human gliblastoma genes and core pathways. Nature 455:1061–1068. CrossRefGoogle Scholar
  14. 14.
    David A, Fruman CR (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140–156. CrossRefGoogle Scholar
  15. 15.
    Li X, Wu C, Chen N et al (2016) PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7:33440–33450. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Luchman HA, Stechishin ODM, Nguyen SA et al (2014) Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res 20:5756–5767. CrossRefPubMedGoogle Scholar
  17. 17.
    Sasaki H, Zlatescu MC, Betensky RA et al (2001) PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159:359–367. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sano T, Lin H, Chen X et al (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820–1824PubMedGoogle Scholar
  19. 19.
    Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256CrossRefGoogle Scholar
  20. 20.
    Nakamura JL, Garcia E, Pieper RO (2008) S6K1 plays a key role in glial transformation. Cancer Res 68:6516–6523. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chinnaiyan P, Won M, Wen PY et al (2018) A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG oncology RTOG 0913. Neuro-Oncology 20:666–673. CrossRefPubMedGoogle Scholar
  22. 22.
    Wen PY, Chang SM, Lamborn KR et al (2014) Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: north American brain tumor consortium trial 04-02. Neuro-Oncology 16:567–578. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Reardon DA, Desjardins A, Vredenburgh JJ et al (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neuro-Oncol 96:219–230. CrossRefGoogle Scholar
  24. 24.
    Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Karen F, Ian Robins H, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Janet Dancey MDP (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investig New Drugs 23:357–361. CrossRefGoogle Scholar
  25. 25.
    Wick W, Gorlia T, Bady P et al (2016) Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res. CrossRefGoogle Scholar
  26. 26.
    Mellinghoff IK, Cloughesy TF, Mischel PS (2007) PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 13:378–381. CrossRefPubMedGoogle Scholar
  27. 27.
    O’Brien NA, Browne BC, Chow L et al (2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:1489–1502. CrossRefPubMedGoogle Scholar
  28. 28.
    Priulla M, Calastretti A, Bruno P, Amalia A, Paradiso A, Canti G, Nicolin A (2007) Preferential Chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 67:782–789. CrossRefPubMedGoogle Scholar
  29. 29.
    Sequist LV, Waltman BA, Dias-santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:1–27. CrossRefGoogle Scholar
  30. 30.
    Momota H, Nerio E, Holland EC (2005) Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65:7429–7435. CrossRefPubMedGoogle Scholar
  31. 31.
    Jiang Z, Pore N, Cerniglia GJ et al (2007) Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67:4467–4473. CrossRefPubMedGoogle Scholar
  32. 32.
    Pike KG, Malagu K, Hummersone MG et al (2013) Bioorganic & medicinal chemistry letters optimization of potent and selective dual mTORC1 and mTORC2 inhibitors : the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 23:1212–1216. CrossRefPubMedGoogle Scholar
  33. 33.
    Wen PY, Macdonald DR, Reardon DA et al (2010) Updated Response Assessment Criteria for High-Grade Gliomas : Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28. CrossRefGoogle Scholar
  34. 34.
    Wen PY, Omuro A, Ahluwalia MS et al (2015) Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-Oncology 17:1275–1283. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Stupp R, Mason WP, Van Den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. CrossRefPubMedGoogle Scholar
  36. 36.
    Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology 11:69–79. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10:143–153. CrossRefPubMedGoogle Scholar
  38. 38.
    Schmid P, Zaiss M, Harper-Wynne C et al (2018) MANTA - a randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Cancer Res 78:GS2-07-GS2-07.
  39. 39.
    Powles T, Wheater M, Din O et al (2016) A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur Urol 69:450–456. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Sarah Lapointe
    • 1
    • 2
  • Warren Mason
    • 2
  • Mary MacNeil
    • 3
  • Craig Harlos
    • 4
  • Roger Tsang
    • 5
  • Joana Sederias
    • 6
  • H. Artee Luchman
    • 7
  • Samuel Weiss
    • 7
  • John P. Rossiter
    • 8
  • Dongsheng Tu
    • 6
  • Lesley Seymour
    • 6
  • Martin Smoragiewicz
    • 6
    Email author
  1. 1.Division of NeurologyCentre Hospitalier de l’Université de MontréalMontréalCanada
  2. 2.Division of Neuro-Oncology, Pencer Brain Tumor CenterUniversity Health Network-Princess Margaret HospitalTorontoCanada
  3. 3.QEII Health Sciences CentreHalifaxCanada
  4. 4.CancerCare ManitobaWinnipegCanada
  5. 5.Tom Baker Cancer CenterCalgaryCanada
  6. 6.Canadian Cancer Trials GroupQueen’s UniversityKingstonCanada
  7. 7.Arnie Charbonneau Cancer Institute & Hotchkiss Brain Institute, Cumming School of MedicineUniversity of CalgaryCalgaryCanada
  8. 8.Department of Pathology and Molecular MedicineQueen’s UniversityKingstonCanada

Personalised recommendations